Harrow (FRA:3IP) Institutional Ownership: 30.71% (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3IP Harrow Inc FRA:3IP
76 GF Score
Price €33.00
GF Value €36.67
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Harrow Institutional Ownership?

Harrow FRA:3IP -0.60% 76 Institutional Ownership is 30.71% as of Aug. 20, 2026. GuruFocus rates FRA:3IP with a GF Score™ of 76/100 and a GF Value™ of €36.67 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Harrow's institutional ownership is 30.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Harrow's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Harrow's Float Percentage Of Total Shares Outstanding is 89.87%.

Harrow Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Harrow's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harrow Institutional Ownership Chart

Harrow Historical Data

The historical data trend for Harrow can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 26.16 26.61 25.56 25.67 26.20 25.47 25.30 24.63 30.46 30.71
FRA:3IP
76GF Score
Harrow Inc FRA:3IP
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harrow Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 30.71% mean?
Harrow (FRA:3IP) has a Institutional Ownership of 30.71% as of Aug. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Harrow and its competitors.
Is Harrow's Institutional Ownership too high?
Harrow's current Institutional Ownership is 30.71%. Overall, Harrow has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harrow's Institutional Ownership compare to XERS and PRGO?
Harrow's Institutional Ownership of 30.71% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Harrow and its competitors. Harrow's current Institutional Ownership is 30.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (FRA:3IP) is currently considered Modestly Undervalued. The stock's GF Value™ is €36.67, compared to a current price of €33.00 — trading 10% below its estimated fair value. The current Institutional Ownership is 30.71%. Harrow's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Harrow (FRA:3IP), the current Institutional Ownership is 30.71% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harrow (FRA:3IP) Overvalued in 2026?

Based on GuruFocus' analysis, Harrow stock appears to be undervalued. The current stock price of €33.00 is trading 10% below its estimated GF Value™ of €36.67. GuruFocus considers Harrow to be Modestly Undervalued.

Key valuation signals for FRA:3IP:

  • Institutional Ownership: 30.71%
  • GF Value™: €36.67 vs. price of €33.00 (10% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the FRA:3IP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harrow Business Description

Other Exchanges HROW:USA
Address 1A Burton Hills Boulevard, Suite 200, Nashville, TN, USA, 37215
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
76GF Score

Get the complete analysis for FRA:3IP

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.00
Price
€36.67
GF Value